Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
23 Apr 2024
Historique:
received: 20 02 2024
revised: 15 04 2024
accepted: 19 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 10 5 2024
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with high mortality due to early metastatic dissemination and high chemoresistance. All these factors are favored by its extracellular matrix (ECM)-rich microenvironment, which is also highly hypoxic and acidic. Gemcitabine (GEM) is still the first-line therapy in PDAC. However, it is quickly deaminated to its inactive metabolite. Several GEM prodrugs have emerged to improve its cytotoxicity. Here, we analyzed how the acidic/hypoxic tumor microenvironment (TME) affects the response of PDAC cell death and invadopodia-mediated ECM proteolysis to both GEM and its C18 prodrug. For this, two PDAC cell lines, PANC-1 and Mia PaCa-2 were adapted to pH We found that C18 has higher cytotoxic and anti-invadopodia activity than GEM in all culture conditions and especially in acid and hypoxic environments. We propose C18 as a more effective approach to conventional GEM in developing new therapeutic strategies overcoming PDAC chemoresistance.

Sections du résumé

BACKGROUND BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with high mortality due to early metastatic dissemination and high chemoresistance. All these factors are favored by its extracellular matrix (ECM)-rich microenvironment, which is also highly hypoxic and acidic. Gemcitabine (GEM) is still the first-line therapy in PDAC. However, it is quickly deaminated to its inactive metabolite. Several GEM prodrugs have emerged to improve its cytotoxicity. Here, we analyzed how the acidic/hypoxic tumor microenvironment (TME) affects the response of PDAC cell death and invadopodia-mediated ECM proteolysis to both GEM and its C18 prodrug.
METHODS METHODS
For this, two PDAC cell lines, PANC-1 and Mia PaCa-2 were adapted to pH
RESULTS RESULTS
We found that C18 has higher cytotoxic and anti-invadopodia activity than GEM in all culture conditions and especially in acid and hypoxic environments.
CONCLUSIONS CONCLUSIONS
We propose C18 as a more effective approach to conventional GEM in developing new therapeutic strategies overcoming PDAC chemoresistance.

Identifiants

pubmed: 38727266
pii: cells13090730
doi: 10.3390/cells13090730
pii:
doi:

Substances chimiques

Deoxycytidine 0W860991D6
Gemcitabine 0
Prodrugs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Marie Curie Innovative Training Program (ITN) "pH and Ion Transport in Pancreatic Cancer-pHioniC
ID : 813834; H2020-MSCA-ITN-2018
Organisme : National Center for Gene Therapy and Drugs based on RNA Technology - PNRR per la Missione 4, componente 2-investimento 1.4
ID : CN00000041
Organisme : PRIN 2022 "AdaPtiviTy"
ID : 20227YTZE3
Organisme : PRIN 2022 PNRR "PhOXyOmicGEM"
ID : P2022L5HAZ

Auteurs

Tiago M A Carvalho (TMA)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Madelaine Magalì Audero (MM)

U1003 PHYCEL Laboratoire de Physiologie Cellulaire, Inserm, University of Lille, 59000 Lille, France.

Maria Raffaella Greco (MR)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Marilena Ardone (M)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Teresa Maggi (T)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Rosanna Mallamaci (R)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Barbara Rolando (B)

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.

Silvia Arpicco (S)

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy.

Federico Alessandro Ruffinatti (FA)

Laboratory of Cellular and Molecular Angiogenesis, Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.

Alessandra Fiorio Pla (AF)

U1003 PHYCEL Laboratoire de Physiologie Cellulaire, Inserm, University of Lille, 59000 Lille, France.
Laboratory of Cellular and Molecular Angiogenesis, Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.

Natalia Prevarskaya (N)

U1003 PHYCEL Laboratoire de Physiologie Cellulaire, Inserm, University of Lille, 59000 Lille, France.

Tomas Koltai (T)

Hospital del Centro Gallego de Buenos Aires, Buenos Aires 2199, Argentina.

Stephan J Reshkin (SJ)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Rosa Angela Cardone (RA)

Department of Biosciences, Biotechnology and Environment, University of Bari, 70125 Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH